These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 22633071)

  • 1. [Gap junctional intercellular communication: a new mechanism in pathophysiology of migraine with aura. Therapeutic applications].
    Sarrouilhe D; Dejean C
    Pathol Biol (Paris); 2012 Dec; 60(6):392-8. PubMed ID: 22633071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of gap junction channels in the pathophysiology of migraine with aura.
    Sarrouilhe D; Dejean C; Mesnil M
    Front Physiol; 2014; 5():78. PubMed ID: 24611055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ; Ferrari MD; Csanyi A; Olesen J; Mills JG;
    Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tonabersat, a novel gap-junction modulator for the prevention of migraine.
    Silberstein SD
    Cephalalgia; 2009 Nov; 29 Suppl 2():28-35. PubMed ID: 19723123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine.
    Durham PL; Garrett FG
    Cephalalgia; 2009 Nov; 29 Suppl 2(Suppl 2):1-6. PubMed ID: 19723120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.
    Hauge AW; Asghar MS; Schytz HW; Christensen K; Olesen J
    Lancet Neurol; 2009 Aug; 8(8):718-23. PubMed ID: 19570717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are cortical spreading depression and headache in migraine causally linked?
    Wolthausen J; Sternberg S; Gerloff C; May A
    Cephalalgia; 2009 Feb; 29(2):244-9. PubMed ID: 19025548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Migraine and cortical spreading depression].
    Alemdar M; Selekler M
    Agri; 2006 Oct; 18(4):24-30. PubMed ID: 17457710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura.
    Garza I
    Curr Neurol Neurosci Rep; 2010 Jan; 10(1):7-9. PubMed ID: 20425219
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent advances in understanding migraine mechanisms, molecules and therapeutics.
    Goadsby PJ
    Trends Mol Med; 2007 Jan; 13(1):39-44. PubMed ID: 17141570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura].
    Richter F; Lehmenkühler A
    Schmerz; 2008 Oct; 22(5):544-6, 548-50. PubMed ID: 18483750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling.
    Damodaram S; Thalakoti S; Freeman SE; Garrett FG; Durham PL
    Headache; 2009 Jan; 49(1):5-20. PubMed ID: 19125874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura.
    Holland PR; Akerman S; Andreou AP; Karsan N; Wemmie JA; Goadsby PJ
    Ann Neurol; 2012 Oct; 72(4):559-63. PubMed ID: 23109150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the methodology of drug trials in migraine with aura.
    Hauge AW; Hougaard A; Olesen J
    Cephalalgia; 2010 Sep; 30(9):1041-8. PubMed ID: 20713554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From spreading depression to the trigeminovascular system.
    Dalkara T; Zervas NT; Moskowitz MA
    Neurol Sci; 2006 May; 27 Suppl 2():S86-90. PubMed ID: 16688636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ Gap junctional intercellular communication].
    Verrecchia F; Farge-Bancel D
    Pathol Biol (Paris); 2012 Dec; 60(6):333. PubMed ID: 23206435
    [No Abstract]   [Full Text] [Related]  

  • 17. The pathophysiology of migraine: year 2005.
    Buzzi MG; Moskowitz MA
    J Headache Pain; 2005 Jun; 6(3):105-11. PubMed ID: 16355290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current views on the pathogenesis of migraine aura].
    Domitrz I
    Neurol Neurochir Pol; 2007; 41(1):70-5. PubMed ID: 17330183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of prophylactic medications on TMS for migraine aura.
    Almaraz AC; Dilli E; Dodick DW
    Headache; 2010 Nov; 50(10):1630-3. PubMed ID: 21198566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
    Dahlöf CG; Hauge AW; Olesen J
    Cephalalgia; 2009 Nov; 29 Suppl 2():7-16. PubMed ID: 19723121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.